Researchers have identified a drug that blocks inflammation-driving molecules in diabetes, opening a path to future cure options.
NEW YORK: A breakthrough study by scientists at the University at Albany and NYU Grossman School of Medicine may pave the way for new treatments that directly target the cause of diabetes-related complications—offering hope for both type 1 and type 2 patients.
The research team successfully developed a small-molecule drug capable of blocking a key cellular pathway that drives chronic inflammation and impairs healing in people with diabetes. Their findings could lead to therapies that address complications at the source, not just manage symptoms.
“Current treatments for diabetes primarily focus on slowing disease progression; however, they do not address the underlying inflammation that contributes to the complications of diabetes,” said Professor Alexander Shekhtman of the University at Albany’s Department of Chemistry and RNA Institute. “Our findings point to a promising new pathway for treating diabetes in the future.”
The researchers focused on molecules known as “advanced glycation end products” (AGEs), which build up in diabetic patients’ tissues and activate a receptor called RAGE. This receptor then triggers another molecule—Diaphanous-1 (DIAPH1)—inside cells. While DIAPH1 normally supports cell function, overstimulation leads to persistent inflammation, cardiovascular issues, and poor wound healing.
Using advanced structural biology, the team identified how RAGE activates DIAPH1 and located a key binding site on the molecule. This allowed them to design a compound that disrupts the damaging chain reaction, effectively halting inflammation at the molecular level.
Importantly, the findings not only provide a potential therapeutic option for both forms of diabetes but also help scientists design biomarkers that track how well new treatments work in real time.
The study marks a significant step toward treating the root causes of diabetic complications, rather than managing surface-level symptoms—offering new hope to millions living with the condition.
